Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It is primarily used in the treatment of inflammatory diseases such as rheumatoid arthritis and, more recently, severe cases of COVID-19. By inhibiting IL-6, a cytokine involved in the inflammatory response, tocilizumab can reduce inflammation and improve clinical outcomes in patients suffering from these conditions.
